Vanessa Kachadurian Bioscience - Strong Dividend Meridian Bioscience

Shares of Meridian Bioscience (NASDAQ:VIVO) saw unusually-strong trading volume on Friday following a dividend announcement from the company, ARN reports. Approximately 488,537 shares traded hands during trading, an increase of 56% from the previous session’s volume of 313,124 shares.The stock last traded at $17.69 and had previously closed at $17.34.
The newly announced dividend is will be paid on Friday, February 13th. Stockholders of record on Monday, February 2nd will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.61%. The ex-dividend date is Thursday, January 29th.
A number of analysts have recently weighed in on VIVO shares. Analysts at Craig Hallum upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and raised their price target for the stock from $19.00 to $22.00 in a research note on Friday. Analysts at Zacks upgraded shares of Meridian Bioscience from an “underperform” rating to a “neutral” rating and set a $17.00 price target on the stock in a research note on Monday, January 12th. Analysts at Raymond James downgraded shares of Meridian Bioscience from a “market perform” rating to an “underperform” rating in a research note on Friday, January 2nd. Finally, analysts at TheStreet downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, December 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Meridian Bioscience currently has an average rating of “Hold” and an average price target of $20.50.
The stock has a 50-day moving average of $16.67 and a 200-day moving average of $18.17. The company has a market cap of $739.2 million and a price-to-earnings ratio of 20.89.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings data on Thursday, January 22nd. The company reported $0.19 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.19. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $46.20 million. Analysts expect that Meridian Bioscience will post $0.86 EPS for the current fiscal year.
Meridian Bioscience, Inc (NASDAQ:VIVO) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Vanessa Kachadurian Bioscience Fund of Connecticut

Vanessa Kachadurian Bioscience researches the states of America and how each are establishing funds for Bioscience industry.  Is this a smart move?  Vanessa Kachadurian thinks so for many reasons. 1) builds the economy and jobs  2) keeps technology in the USA   3)  Encourages more Americans to get into research and development.

Rocky Hill, Conn. (PRWEB) December 23, 2013

Connecticut Innovations (CI), the state’s quasi-public authority responsible for helping businesses grow through innovative financing and strategic assistance, today announced the names of the appointees to the 13-member Bioscience Innovation Advisory Committee, which will steer the direction of the $200 million Connecticut Bioscience Innovation Fund (CBIF) and approve expenditures. CI executive vice president and chief innovation officer Jeremy Crisp, Ph.D., a former Novartis Institutes for BioMedical Research executive, was hired earlier this year to lead the CBIF. The committee held its first official meeting on December 5.

In July, Governor Dannel P. Malloy signed Public Act 13-239 into law to create the CBIF, establish an Advisory Committee to oversee the fund's operations and require CI to administer the fund under the committee's supervision. Under the statute, the governor appointed four members to the committee while the president pro tempore of the state senate, speaker of the house, and majority and minority leader of both chambers appointed one member each. The commissioners of the state’s Department of Economic and Community Development and Department of Public Health or their designees serve as ex-officio voting members, and CI’s chief executive officer and executive director will serve as committee chairperson. Appointed members were selected based on their skill, knowledge and experience in relevant businesses and sciences related to health care delivery, medical devices, life sciences, insurance or information technology.

"We are delighted to have attracted such high caliber individuals to the advisory committee," said Claire Leonardi, CEO of Connecticut Innovations. "Their collective depth and breadth of experience across the bioscience spectrum will ensure great stewardship of the fund."

The new board members are Peter Farina, Ph.D., executive in residence, Canaan Partners; Steven Hanks, M.D., vice president of medical affairs for Hartford HealthCare - Central Region; Joseph Kaliko, J.D., chief executive officer of Gaming Innovations International; Marc Lalande, Ph.D., Health Net Professor and chair of the Department of Genetics and Developmental Biology, and executive director of Genomics and Personalized Medicine Programs, UConn; William LaRochelle, Ph.D., head of healthcare and key opinion leader management, Roche 454 Sequencing Solutions International; Charles Lee, Ph.D., scientific director, The Jackson Laboratory for Genomic Medicine; Jewel Mullen, M.D., commissioner, Connecticut Department of Public Health (ex-officio); Claire Leonardi, chief executive officer of Connecticut Innovations (chair); Alan Mendelson, general partner, Axiom Venture Partners; Edmund Pezalla, M.D., M.P.H., national medical director for pharmaceutical policy, Aetna; Carolyn Slayman, Ph.D., Sterling Professor of Genetics, professor of cellular and molecular physiology and deputy dean, Yale School of Medicine; Catherine Smith, commissioner, Department of Economic and Community Development (ex-officio); and Eleanor Tandler, founder and chief executive officer, Novatract Surgical.

About Peter Farina, Ph.D.
Peter Farina, Ph.D., of North Salem, New York, is an executive in residence at Canaan Partners, a venture capital firm located in Westport, Conn., where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology LLC, which advises several U.S. and Chinese biotech firms on strategic and technical matters in pharmaceutical research and development. Farina serves as co-chair of Connecticut United for Research Excellence (CURE) board and a member of the advisory board of the University of Connecticut School of Pharmacy, the NIH Blueprint Neurotherapeutics Network (BPN) steering committee, and the Emory University DRIVE Advisory Board. Additionally, he was a founder and chief executive officer of Developing World Cures, a nonprofit company working on neglected diseases.

About Steven Hanks, M.D.
Steven D. Hanks, M.D., M.M.M., F.A.C.P., F.F.S.M.B., of Farmington, Connecticut, is vice president of medical affairs for Hartford HealthCare’s central region. He is the former executive vice president and chief medical officer for The Hospital of Central Connecticut (THOCC). Hanks has been and will continue to serve as THOCC’s chief academic officer and remains the assistant dean for graduate medical education at the University of Connecticut. An internist and emergency physician, Hanks joined THOCC in 2004 from the Finger Lakes Regional Health System, where he served as senior vice president of medical affairs and chief medical officer. Prior to that he was chief medical officer of Adroit Research Solutions, a doctor's research organization that he co-founded, as well as chief medical officer of the Rochester Community Individual Practice Association, at the time one of the largest IPAs in the nation.

About Joseph J. Kaliko
Joseph J. Kaliko of Greenwich, Connecticut, serves as president and chief executive officer of Gaming Innovations International LLC, which designs innovative gaming products and services for lotteries and their suppliers internationally. He is a member of the Connecticut and Ohio bars and is registered to practice as a patent attorney before the United States Patent and Trademark Office. As an inventor, Kaliko has been awarded patents that have been used to launch businesses in the U.S. and abroad.

About Marc Lalande, Ph.D.
Marc Lalande, Ph.D., of West Hartford, Connecticut, is Health Net Professor and chair of the Department of Genetics and Developmental Biology and executive director of Genomics and Personalized Medicine Programs at the University of Connecticut. He received a Ph.D. in medical biophysics from the University of Toronto in 1981. His postdoctoral training was with Samuel A. Latt, M.D, Ph.D., in the Department of Pediatrics, Harvard Medical School and Children's Hospital, Boston, Mass. From 1985 to 1988, he was assistant professor, Department of Pathology and Center for Human Genetics, McGill University, in Montreal, Quebec, before returning to Boston Children’s Hospital. He remained at Harvard Medical School until 1998, where he was an associate professor of pediatrics and an assistant investigator of the Howard Hughes Medical Institute.

About William J. LaRochelle, Ph.D.
William LaRochelle, Ph.D., of Madison, Connecticut, is currently a member of the Roche 454 Sequencing Solutions International Business Team and head of key opinion leader management. In addition, he is the Roche 454 global liaison to Genentech, Roche Pharma, Chugai

Pharmaceutical Co. and external key opinion leaders for Roche’s personalized healthcare strategy in cancer genomic medicine. He has over 25 years of translational research and drug development experience beginning with 13 years at the National Cancer Institute, Bethesda, Md., and almost 13 years at CuraGen/454 Corporation, Branford, Conn.

About Charles Lee, Ph.D.
Charles Lee, Ph.D., of Farmington, Connecticut, is the scientific director of The Jackson Laboratory for Genomic Medicine. Prior to joining the laboratory, Lee was director of the Molecular Genetic Research Unit at Brigham and Women’s Hospital, an associate professor at Harvard Medical School, and a board-certified clinical cytogeneticist. He received his doctoral degree from the University of Alberta, Canada; completed a research fellowship at Cambridge University, England; and conducted his clinical training at Harvard Medical School.

About Commissioner Jewel Mullen, M.D.
Jewel Mullen, M.D., of Middlefield, Connecticut, oversees the state’s leading public health agency as commissioner of the Connecticut Department of Public Health. Appointed to this position by Governor Dannel Malloy in December 2010, Dr. Mullen has combined clinical work, research, teaching and administration throughout a career focused on improving the health of all people, especially the underserved.

About Claire Leonardi
Claire Leonardi of Avon, Connecticut, is chief executive officer of Connecticut Innovations, where she manages the organization’s full array of business startup and growth initiatives, which include diverse lending programs, venture and equity investment funds, and programs to support innovation, entrepreneurship, collaboration and commercialization. Claire is a veteran investment and venture capital executive with more than 30 years of experience in the financial services industry. Leonardi will serve as committee chairperson.

About Alan Mendelson
Alan Mendelson of West Hartford, Connecticut, is the founder and a general partner of Axiom Venture Partners. Prior to founding Axiom Venture Partners, Mendelson had a 24-year career in investments at Aetna Life & Casualty in Hartford, Conn., where he was involved in more than $3 billion of private placement debt financings with estimated combined losses of under $10 million. During his final six years with Aetna, he focused its venture investing on the medical/healthcare area, where he made a number of successful investments, including investments in GMIS, Geron, Human Genome Sciences and SyStemix. In several of these companies, he was a founding investor, and in the case of SyStemix, also its de facto chief executive officer. Overall, the $65 million portfolio of direct investments generated approximately $265 million of proceeds.

About Edmund Pezalla, M.D.
Edmund Pezalla, M.D., M.P.H., of Wethersfield, Connecticut, is Aetna’s national medical director for pharmaceutical policy and strategy. He is responsible for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. He also serves as the lead clinical spokesperson for Aetna in pharmacy-related issues and represents Aetna on industry work groups and conferences. He is Aetna’s leading executive on pharmaceutical development, reimbursement strategy and drug evaluation. He is active on projects with the IOM, CDC and FDA as well as MIT’s Center for Biomedical Innovation. Recently, Pezalla served as a consultant for the President’s Council of Advisors on Science and Technology for their report “Propelling Innovation in Drug Discovery, Development and Evaluation.”

About Carolyn Slayman, Ph.D.
Carolyn Slayman, Ph.D., of Hamden, Connecticut, is the deputy dean of Yale School of Medicine (YSM), where she is also Sterling Professor of Genetics and a professor of cellular and molecular physiology and heads a laboratory focusing on the biogenesis and molecular mechanisms of membrane transport proteins. She chaired the medical school’s Department of Genetics for 11 years, and since then has served as deputy dean for academic and scientific affairs. In the latter role, she has broad oversight of YSM research, working with the heads of the school’s 29 departments and five interdepartmental centers to recruit faculty, launch new areas of investigation, and stimulate partnerships and collaborations. She also participates on behalf of YSM in the development of Yale’s new West Campus (purchased from the Bayer Pharmaceutical Company in 2007), where work is underway to form interdisciplinary institutes in areas including biodesign, cancer biology, chemical biology, microbial diversity, and systems biology.

About Commissioner Catherine Smith
Catherine Smith of Northford, Connecticut, is commissioner of the Connecticut Department of Economic and Community Development (DECD), the lead state agency responsible for attracting and retaining businesses and jobs, revitalizing neighborhoods and communities, expanding affordable housing opportunities and fostering appropriate development in Connecticut’s towns and cities. Governor Dannel P. Malloy appointed her to the position in April 2011. Prior to joining DECD, Commissioner Smith had a distinguished career in the insurance and financial services industry, beginning with Aetna in 1983.

About Eleanor L. Tandler
Eleanor L. Tandler of Guilford, Connecticut, is the founder and chief executive officer of NovaTract Surgical Inc. Prior to NovaTract, Tandler was the director of venture development at the University of Connecticut Research and Development Corporation (UConn R&D), where she worked to create new business startups based on innovative technologies developed by the faculty and staff at the university. During her tenure at UConn R&D, she served as interim chief executive officer of New Ortho Polymers, a UConn startup focused on the development of new orthodontic appliances based on utilizing high-performance polymers. Prior to that, she spent five years as a venture capital investor with Radius Ventures, an early-stage venture capital firm focused on health and life sciences with approximately $230 million under management.

About Connecticut Innovations Inc.
Connecticut Innovations (CI) is the leading source of financing and ongoing support for Connecticut's innovative, growing companies. To maximize the growth potential of each business, CI tailors its solutions and often combines its funds with resources from other financial leaders to provide venture capital and strategic support for early-stage technology companies; flexible loans for established companies with new innovations; grants that support innovation and collaboration; and connections to its well-established network of partners and professionals. Through all these initiatives, CI has helped bring $4 billion in financing to Connecticut companies. The state’s most active early-stage investor, CI has created more than 26,000 jobs. For more information on CI, please visit http://www.ctinnovations.com.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11446155.htm

Read more: http://www.digitaljournal.com/pr/1655835#ixzz2p60bkYyu

Vanessa Kachadurian, Bioscience spotlight on Semprus Bioscience preventing complications from medical device implants

Any medical device implanted in the body attracts bacteria, proteins, and other microbes to its surface, causing infections and thrombosis (blood clotting) that lead to hundreds of thousands of deaths annually. Devices can be coated with antibiotics, blood thinners, and other agents – but these eventually dissolve, limiting their longevity and effectiveness.

Now, Semprus BioSciences, a startup co-founded by two MIT alumni – Christopher Loose PhD ’07 and CEO David Lucchino MBA ’06 – is developing a novel biomaterial for implanted medical devices that permanently barricades these troublesome microbes from the device’s surface.

The biomaterial is a nonleaching polymeric sulfobetaine (polySB) that, when applied to a medical device, sprouts a thicket of polymers that attract water, creating an impenetrable barrier for microbes. Its chemical makeup also mimics that of cells important to homeostasis, potentially reducing the body’s natural rejection of implanted devices.

“Basically, we’ve developed a long-lasting solution that blocks negative consequences in the body by making devices look more like the human body,” Loose says.

The application of polySB to catheters yields a significant reduction in the buildup of protein, mammalian cells, and microbes on a device’s surface, compared with unmodified catheters. This has potential to reduce blood clots and infection, and improve overall patient health, the co-founders say.

The technology was described in a paper published last year in the journal Science Translation Medicine, co-authored by Loose, Lucchino, MIT Institute Professor Robert Langer, and other researchers.

Based on Loose’s work at MIT, the biomaterial has positioned Semprus as a fast-growing biotech firm in Kendall Square. In its six years, the startup – seed-funded, in part, by the MIT $100K Entrepreneurship Competition – has earned millions of dollars in private and federal funding. In 2012, Semprus sold to a medical device-manufacturing giant for an amount that could reach $80 million. As a wholly owned subsidiary, the Semprus team continues developing the technology.

Semprus’ first commercial product based on the biomaterial, Semprus Sustain technology, is designed specifically for venous catheters and recently earned clearance from the Food and Drug Administration as a medical device deemed safe and effective for commercial distribution in the United States. It also recently received designation as a product meeting European Union standards of health, safety, and environmental protection.

Addressing an ‘unmet need’
The Semprus story began in Langer’s lab, where Loose, a chemical engineering PhD student, was charged with developing medical devices that could permanently be inserted in the body without triggering an immune response – in other words, creating medical devices that “looked more human,” Loose says.

Loose developed a means of applying naturally occurring antibiotics, called antimicrobial peptides – found in bacteria and human sweat – on medical devices. These peptides would puncture bacteria that came near, and microbes would have trouble developing resistance to them. In 2007, Loose was named one of “35 innovators under 35” by MIT Technology Review for this innovation.

Seeing commercial potential, Langer – a chemical engineer, bioengineer, and famed MIT entrepreneur – “played matchmaker” between Loose and Lucchino, who had previously worked for Polaris Ventures Partners and was, at the time, an Alfred P. Sloan Fellow at the MIT Sloan School of Management.

The two had an instant rapport, Lucchino says – and an ambition to commercialize Loose’s innovation. So they “went to school” on the medical-device market, canvassing hospitals to meet patients and to talk with nurses and doctors about unmet clinical needs.

“We learned quickly that the most successful entrepreneurs are good listeners,” Lucchino says. “We conducted our own ‘listening tour’ to understand the problem, so we could develop the most strategic business and technology solution.”

They found many patients suffering from chronic diseases – such as diabetes, cancer, and heart disease – and a lack of permanent “coatings” for medical implants that might help these patients. Thus, Loose says, they were ahead of the curve in addressing the “unmet need” of the medical devices market.

“We realized an unmet need that was going to grow over the next few years and we were one of the first to have a solution to it,” he says. “Everything starts with the unmet need.”

Today, the Semprus technology has proven its effectiveness. In the Science Translation Medicine paper, the co-founders exposed polySB-modified catheters to blood for 60 days. In vitro, the modified catheters – on both their external and internal surfaces – saw a 98% reduction in the accumulation of platelets and three types of white blood cells. Additionally, thrombotic material on the device was reduced by 99%. In vivo, the modified catheters showed a 99 percent reduction in thrombus accumulation, 50% less inflammation, and fewer bacteria.

‘A pathway’ for a startup
A catalyst for starting Semprus was winning MIT’s $100K (as SteriCoat) in 2006, and going on to win similar business-plan competitions at Harvard and Oxford universities.

“Once we had clear confirmation that there was an enormous unmet need, in terms of cost and patient impact, we had a clear business plan refined through the competitions, and even more so thereafter,” Loose says. “It gave us a pathway to say, ‘This is how we can solve a big problem and here’s the pathway to do it.’”

The two were also “very diligent in going to any networking and entrepreneur event at MIT. There is a tremendous [number] of MIT alumni, very open with their time, who provided critical support and advice,” Loose says.

Through MIT’s network of entrepreneurs, investors, and lawyers, “we were able to assemble a great team of advisers to refine our plans and give us the momentum to go out and do financing,” Lucchino says.

Under Lucchino’s stewardship, Semprus secured $28.5 million in venture capital financing and $2.4 million in federal funding, primarily from the National Science Foundation, and grew from two to 40 employees.

Lucchino says he owes some of his business acumen to his education at MIT Sloan, which taught him a broad set of entrepreneurial skills in finance, business, and operations strategies. “It was continuing to fertilize my entrepreneurial soil to get me in the best position to succeed,” Lucchino says.

Today, the two entrepreneurs continue to mentor students and give talks at MIT and Harvard Business School, sharing startup advice, or their “rules of the road” – such as knowing your technological and personal limitations, working with limited resources, being flexible to economic and other changes, and, most importantly, teamwork.

“No one person builds a company alone,” says Lucchino, who has served as guest lecturer at MIT Sloan. “As your company grows and there’s real value attached to what you’re doing, you need to be able to trust the people you’re working with. Chris and I, as a team, made Semprus a success. The most important skill and functionality we have is trust.”

Source: MIT News

http://www.onlinetmd.com/semprus-bioscience-medical-developments-123013.aspx

 

Vanessa Kachadurian Teaches Businesses To Sell | Segment News

Here is the accompanying article from Segment News, thank you my Journalist friends.


Most people have to sell something to someone at some point in their lives, and knows the task is sometimes daunting. But effective sales techniques are important for individuals and businesses to learn and incorporate. Everyone is in sales, no matter what their “profession” is.

Every once in a while, everyone is called on to sell something. People sell products, services, plans, ideas and beliefs. Sales is a positive thing, in and of itself. While many sales myths persist, most often people sell things of value—things that matter.

Vanessa Kachadurian built a career selling medical devices and supplies. The products she sold helped numerous people achieve relief from their ailments and receive better care from their health care providers.

Without sales, the economy and much of the way people understand the world simply would not exist. People sell themselves to get jobs, children sell ideas in school, researchers sell their knowledge and products are created. Sales is little more than effective communication, and Vanessa Kachadurian believes the following tips will help anyone learn to sell.

Ditch the Pitch. This vocabulary makes sales much harder. A pitch, in baseball terms, is something that is either avoided or swung at to bat it away. These are not ideal outcomes for a salesperson. Instead, think of the pitch as a recommendation. During the recommendation listen to the needs of the client and find a way to address those needs with the product. Vanessa Kachadurian argues that listening is more important than talking in these meetings because when a sales person knows their product well they have to hear what a client needs to know how to sell to them.

Honesty matters. Sales professionals must value honesty in their approach at all times. There is a difference between dishonesty and strategic positioning. When selling an idea or a product, outline the truth.

Knowledge is power. Effective sales people know as much as possible about the product, idea or service they are selling. It is a given that when making a sales pitch people are likely to ask questions that the seller does not know the answer to. Admitting this and promising to find an answer and following up is a great remedy to this situation. And follow-up shows dedication and commitment. Vanessa Kachadurian teaches people to present as much information as possible including potential drawbacks and how to address them.

Establish trust with clients. Trust comes from knowledge. During her career, Vanessa Kachadurian quickly established trust with clients by demonstrating expertise on the supplies she was selling. When clients trust the sales person, they believe that they can invest in the product or service and have little worry of future problems. They might also believe that if problems do arise, the company that sold the product will fix the issue.

Connect with clients. Connecting with clients during a sales meeting goes beyond establishing trust. Finding a personal connection between a client, the sales person and the product is essential for closing the deal. Vanessa Kachadurian regularly finds clients who have personal connections to the devices she is selling. By fostering a sense of relationship, she is able to show clients how a product will enhance their lives and businesses. Sales people who take an interest in their clients fare better when making their arguments because the client is comfortable with the seller.

Do not push. There is a difference between strong sales and aggression. Clients are likely to shut down if they feel they are forced into a corner. The decision to buy should come from the client, not the seller. The best sales people make their pitches and let the clients decide what to do next.

Vanessa Kachadurian Urges Businesses to Build Strong Sales Teams

Businesses need effective sales teams to grow. Even doctors, lawyers and other professional service providers have to sell to attract business. Particularly for small and new businesses, training a sales staff is one of the most important tasks leaders will conduct.

Training a sales staff requires in-depth knowledge. One of the biggest mistakes companies make is thinking that sales training is just an overview of the products and services offered, Vanessa Kachadurian notes. Training should take time and allow each member of the sales team to practice in situations similar to actual client meetings. Sales representatives should know where to find answers and have a working knowledge before they hold their first meetings.

The small business administration argues that sales forces should have expert knowledge in order to succeed. Because of technology, customers are more informed about products and competition than ever before, Ms. Kachadurian notes, it is important for sales people to have even more knowledge and skill.

All training of sales teams should include an awareness of any competition. When questions arise about competing products and services, a good sales person should have the ability to address the merits of the competition and position his or her product more favorably.

Without a strong sales force it is nearly impossible for businesses to grow. One-time training is also not enough to ensure continued growth and increased revenues. Sales teams should meet regularly to discuss successful methods and questions they receive. They should also stay abreast of industry developments and competition advancements.

Vanessa Kachadurian understands that for many businesses these measures are costly, but encourages owners to make the investment for the long-term health of their companies.

ABOUT:

Vanessa Kachadurian is a medical professional who built a successful career in sales. She is a driven individual who found success by building relationships and knowing the products she was tasked with selling. By becoming an expert with a highly specialized working knowledge of medical supplies and devices, she successfully raised revenues for the companies she worked for. She earned her bachelor’s degree from National University and graduated cum laude. In 2000 her career began with a position at Cardinal Health and her strong business acumen has propelled her forward ever since. She is of Armenian descent and enjoys promoting her culture through philanthropic activities.

Vanessa Kachadurian Teaches Businesses the Art of Selling by Jon Dye  - See more at: http://segment.com/vanessa-kachadurian-art-of-selling/#sthash.WpK5GdSC.dpuf